[1] |
COUSER W G. Primary membranous nephropathy[J]. Clin J Am Soc Nephrol, 2017, 12(6):983-997.
DOI
URL
|
[2] |
PAN X, XU J, REN H, et al. Changing spectrum of biopsy-proven primary glomerular diseases over the past 15 years:a single-center study in China[J]. Contrib Nephrol, 2013, 181(181):22-30.
|
[3] |
RADHAKRISHNAN J, CATTRAN D C. The KDIGO practice guideline on glomerulonephritis:reading between the(guide)lines-application to the individual patient[J]. Kidney Int, 2012, 82(8):840-856.
DOI
URL
|
[4] |
BECK L H Jr, BONEGIO R G, LAMBEAU G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy[J]. N Engl J Med, 2009, 361(1):11-21.
DOI
URL
|
[5] |
Kidney Disease:Improving Global Outcomes(KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases[J]. Kidney Int, 2021, 100(4S):S1-S276.
DOI
PMID
|
[6] |
陈瑞颖, 鲁鉴达, 谢琼虹, 等. 成人磷脂酶A2受体相关特发性膜性肾病的自然病程和治疗反应的影响因素[J]. 中华肾脏病杂志, 2019, 35(1):1-8.
DOI
|
[7] |
KAGA H, KOMATSUDA A, YAMAMOTO S, et al. Comparison of measurements of anti-PLA2R antibodies in Japanese patients with membranous nephropathy using in-house and commercial ELISA[J]. Clin Exp Nephrol, 2019, 23(4):465-473.
DOI
PMID
|
[8] |
TOMAS N M, BECK L H Jr, MEYER-SCHWESINGER C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy[J]. N Engl J Med, 2014, 371(24):2277-2287.
DOI
URL
|
[9] |
HOXHA E, WIECH T, STAHL P R, et al. A mechanism for cancer-associated membranous nephropathy[J]. N Engl J Med, 2016, 374(20):1995-1996.
DOI
URL
|
[10] |
HOXHA E, BECK LH Jr, WIECH T, et al. An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy[J]. J Am Soc Nephrol, 2017, 28(2):520-531.
DOI
PMID
|
[11] |
SETHI S, DEBIEC H, MADDEN B, et al. Neural epidermal growth factor-like 1 protein(NELL-1) associated membranous nephropathy[J]. Kidney Int, 2020, 97(1):163-174.
DOI
URL
|
[12] |
CAZA T N, HASSEN S I, DVANAJSCAK Z, et al. NELL1 is a target antigen in malignancy-associated membranous nephropathy[J]. Kidney Int, 2021, 99(4):967-976.
DOI
URL
|
[13] |
WANG G, SUN L, DONG H, et al. Neural epidermal growth factor-like 1 protein-positive membranous nephropathy in Chinese patients[J]. Clin J Am Soc Nephrol, 2021, 16(5):727-735.
DOI
URL
|
[14] |
SETHI S, DEBIEC H, MADDEN B, et al. Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients[J]. Kidney Int, 2020, 98(5):1253-1264.
DOI
PMID
|
[15] |
SETHI S, MADDEN B, DEBIEC H, et al. Protocadherin 7-associated membranous nephropathy[J]. J Am Soc Nephrol, 2021, 32(5):1249-1261.
DOI
PMID
|
[16] |
SETHI S, MADDEN B J, DEBIEC H, et al. Exostosin 1/exostosin 2-associated membranous nephropathy[J]. J Am Soc Nephrol, 2019, 30(6):1123-1136.
DOI
PMID
|
[17] |
IWAKURA T, EMA C, ISOBE S, et al. Prevalence of neural epidermal growth factor-like 1- and exostosin 1/exostosin 2-associated membranous nephropathy:a single-center retrospective study in Japan[J]. Sci Rep, 2022, 12(1):2967.
DOI
|
[18] |
AL-RABADI L F, CAZA T, TRIVIN-AVILLACH C, et al. Serine protease HTRA1 as a novel target antigen in primary membranous nephropathy[J]. J Am Soc Nephrol, 2021, 32(7):1666-1681.
DOI
URL
|
[19] |
LI Q, XU M, ZHANG Z, et al. Urinary exosomal hsa_circ_0001250 as a novel diagnostic biomarker of idiopathic membranous nephropathy[J]. J Transl Med, 2022, 20(1):607.
DOI
PMID
|
[20] |
ZHOU G, JIANG N, ZHANG W, et al. Biomarker identification in membranous nephropathy using a long non-coding RNA-mediated competitive endogenous RNA network[J]. Interdiscip Sci, 2021, 13(4):615-623.
DOI
PMID
|
[21] |
DUAN S, CHEN S, LU F, et al. Serum 25-hydroxyvitamin D as a predictive biomarker of clinical outcomes in patients with primary membranous nephropathy[J]. Front Nutr, 2023, 10:1171216.
|
[22] |
李臻, 李贞, 陈伟琴, 等. 血浆纤溶标志物在原发性膜性肾病疾病进展中的变化[J]. 检验医学, 2020, 35(1):25-28.
|